Sunday, September 25, 2022

AIIMS director revealed this about Remedisvir

New Delhi: Increased demand for anti-viral injection remediesvir has increased following increasing cases of corona. Many people can be seen demanding this injection on social media. Now about this injection AIIMS Delhi Director Randeep Guleria has tried to clear the confusion.

“It is important to understand that Remedisvir is not a magic pill nor a mortality reduction drug,” Guleria said in an interview. We can use it because we do not have an anti-viral medicine. It is of no use to give the infected people a mild symptom early. However, it is of no use even when given late.

The Director of Delhi AIIMS said that Remedisavir should be given only to patients admitted to the hospital, whose oxygen drops. Guleria said that in the last one year of corona management we have learned that two things are most important – drugs and timing of drugs.

Read Also:  Remedies of shortage in the country will soon go away, know how

If you give them too early and late, it will cause damage. Giving a cocktail of drugs on the very first day “can kill your patient and will be more harmful.”

The demand for the anti-viral drug Remedisvir, considered a major drug in the fight against COVID-19, has increased after a sudden increase in corona cases.

The Center had on 11 April banned the export of injected remediesvir and remediesvir active pharmaceutical ingredients (APIs) until the Kovid-19 situation in the country improves.

On Monday, again, the highest number of one-day cases of coronovirus cases have been reported, with more than 2.73 lakh fresh infections and 1,619 deaths in the last 24 hours.

Read Also:  Rand Paul reveals his wife's investment in the company behind remdesivir after 16 months


Nation World News Desk
Nation World News Desk
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -